Delpazolid is an investigational antitubercular agent. It is being studied in combination with delamanid and bedaquiline. Delpazolid is a promising oxazolidinone antibiotic being developed for the treatment of TB. Currently in phase II clinical trials, delpazolid has demonstrated improved efficacy and safety compared to linezolid. The recently completed DECODE phase IIb trial evaluated different doses of delpazolid (up to 1200mg once daily) in combination with a backbone regimen of bedaquiline, delamanid, and moxifloxacin for the treatment of pulmonary TB. The study found that delpazolid was safe and well-tolerated, while promising signs of efficacy for drug-sensitive TB. However, the trial had limitations, including a small sample size that resulted in wide confidence intervals and the absence of a standard of care control arm for comparison. Despite these limitations, the trial results suggest delpazolid could be a strong candidate for treating drug-resistant TB. As the clinical data are still immature, the drug candidate remains in the watchlist. The primary patent on delpazolid is filed or granted in key countries of manufacture such as India, China and South Africa and is expected to expire in 2029. Secondary patents with an expected expiry date in 2031 are filed or granted in a few LMICs.

Patent & licence data in LMICs

Acronyms & abbreviations list